Questions and Answers on Practical Thrombotic Issues in SARS-CoV-2 Infection: A Guidance Document from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology

the Italian Study Group on Atherosclerosis, Thrombosis, Vascular Biology

Research output: Contribution to journalReview articlepeer-review

Abstract

In patients with coronavirus disease 2019 (COVID-19), the prevalence of pre-existing cardiovascular diseases is elevated. Moreover, various features, also including pro-thrombotic status, further predispose these patients to increased risk of ischemic cardiovascular events. Thus, the identification of optimal antithrombotic strategies in terms of the risk–benefit ratio and outcome improvement in this setting is crucial. However, debated issues on antithrombotic therapies in patients with COVID-19 are multiple and relevant. In this article, we provide ten questions and answers on risk stratification and antiplatelet/anticoagulant treatments in patients at risk of/with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection based on the scientific evidence gathered during the pandemic.

Original languageEnglish
Pages (from-to)559-570
Number of pages12
JournalAmerican Journal of Cardiovascular Drugs
Volume20
Issue number6
DOIs
Publication statusPublished - Dec 2020
Externally publishedYes

Fingerprint

Dive into the research topics of 'Questions and Answers on Practical Thrombotic Issues in SARS-CoV-2 Infection: A Guidance Document from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology'. Together they form a unique fingerprint.

Cite this